<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357301</url>
  </required_header>
  <id_info>
    <org_study_id>P2020/157</org_study_id>
    <nct_id>NCT04357301</nct_id>
  </id_info>
  <brief_title>Tight Closed-loop Systolic Arterial Pressure Control</brief_title>
  <official_title>Tight Systolic Arterial Pressure Control Using a Closed-loop System for Vasopressor Infusion in Patients Undergoing High-risk Abdominal Surgery: A Feasibility Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this feasibility pilot study is to evaluate the performance of a novel
      closed-loop (automated) vasopressor administration system that delivers norepinephrine using
      feedback from standard operating room hemodynamic monitoring (EV1000 monitoring device,
      Edwards Lifesciences, Irvine, USA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this protocol, the investigators will report the percentage of case time in hypotension
      (defined as systolic arterial pressure (SAP) &lt; 117mmHg). The target mean arterial pressure
      (MAP) will be set at a SAP of 130mmHg in all patients. Definition of Hypotension is target
      SAP - 10% (130mmHg - 13 mmHg = 117 mmHg). We will use the same SAP target in all patients
      even if we used a modified definition of hypotension from the study of Futier and colleagues
      ( JAMA 2017). We won't use a individualized SAP for each patient but the same SAP target in
      all patients.

      The investigators want to demonstrate that the closed-loop system can prevent hypotension at
      this specific set point.

      The Investigators have shown the system works well based on a target MAP but not yet using a
      target of SAP.

      The investigators will test the system in small cohort of 20 patients undergoing High-risk
      abdominal surgery which require the placement of a arterial catheter, the optimization of
      fluid therapy and a tight SAP control.

      Participants will receive standard patient care in that in no way will their anesthetic or
      surgical procedure will be altered as part of the study, with the exception of vasopressor
      administration ( automatically delivery instead of manually adjustments)

      Fluids will be given as goal directed fluid therapy in order to maintain stroke volume
      variation below 13% (hospital guidelines).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single prospective study ( one single cohort of 20 patients)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of case Time in hypotension (SAP &lt;117 mmHg)</measure>
    <time_frame>At postoperative day 1</time_frame>
    <description>The primary outcome will be the percentage of case time in predefined SAP target (SAP of 130 mmHg -10 % = 117 mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of vasopressors received</measure>
    <time_frame>At postoperative day 1</time_frame>
    <description>Amount of vasopressors received (norepinephrine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vasopressors infusion rate modifications</measure>
    <time_frame>At postoperative day 1</time_frame>
    <description>Number of vasopressors infusion rate modifications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of case time with a MAP &lt; 65 mmHg</measure>
    <time_frame>At postoperative day 1</time_frame>
    <description>Percentage of case time with a MAP &lt; 65 mmHg</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Closed-loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Closed-loop administration of norepinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closed-loop vasopressor</intervention_name>
    <description>The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients</description>
    <arm_group_label>Closed-loop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age of &gt;17)

          -  Elective high-risk abdominal surgery

          -  Patients with an arterial line and i whom a Goal directed therapy protocol is applied
             manually

        Exclusion Criteria:

          -  Atrial Fibrillation

          -  Pregnancy

          -  Subjects without the capacity to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Joosten, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ERASME</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Joosten, MD PhD</last_name>
    <phone>025553111</phone>
    <phone_ext>025553111</phone_ext>
    <email>joosten-alexandre@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barvais Luc, M.D Ph.D</last_name>
    <phone>025553111</phone>
    <phone_ext>025553111</phone_ext>
    <email>Luc.Barvais@ulb.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JOOSTEN ALEXANDRE, MD PhD</last_name>
      <email>joosten-alexandre@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Rinehart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Barvais, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime Cannesson, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>July 4, 2020</last_update_submitted>
  <last_update_submitted_qc>July 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Alexandre Joosten, MD PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

